Charles Ramat and Paul Freiman named co-chief executive of Neurotrope
US-based Neurotrope (OTCQB: NTRP), developers of diagnostic and therapeutic technologies for the treatment of neurodegenerative diseases, has announced the appointment of co-chairmen Charles Ramat and Paul Freiman as co-chief executives on an interim basis. They replace James New, who remains on the board of directors, and the board has begun a search for a permanent chief executive.
Mr Ramat is a private investor and has operational and business experience in industries including biotech, medical devices, commercial finance and mobile communications. Mr Freiman is an independent pharmaceutical and biotechnology industry consultant, and serves as chairman of Chronix BioMedical. He has served on the boards of several biotech companies in the USA and Singapore. During his tenure as chairman and chief executive of Syntex Corporation, it was sold to the Roche Group (ROG: SIX) for $5.3 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze